Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data

Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis... Psychopharmacology (2017) 234:2453–2461 DOI 10.1007/s00213-017-4634-5 ORIGINAL INVESTIGATION Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data 1 1 1,2 1 Hitoshi Sakurai & Takefumi Suzuki & Kimio Yoshimura & Masaru Mimura & 1,3 Hiroyuki Uchida Received: 11 August 2016 /Accepted: 20 April 2017 /Published online: 3 May 2017 Springer-Verlag Berlin Heidelberg 2017 Abstract p = 0.001), sleep onset insomnia (HR = 1.129, p =0.047), Background Residual symptoms are detrimental to prognosis and weight change (HR = 1.125, p =0.045). in major depressive disorder (MDD); however, little is known Limitations The original trial was not designed to evaluate the about the contribution of each residual symptom in predicting issue addressed herein. Individual symptoms may be associ- outcomes. The objective of this analysis was to identify which ated with each other and functional status was not addressed. individual symptoms, based on self-report and clinician inter- Conclusions Some residual symptoms, including restless- ness, insomnia, and weight change, may help better identify view, could predict subsequent relapse. Methods The data of 1133 outpatients with nonpsychotic patients with MDD vulnerable to relapse. Contribution of in- MDD who entered a 12-month naturalistic follow-up phase dividual residual symptoms to http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Psychopharmacology Springer Journals

Predicting relapse with individual residual symptoms in major depressive disorder: a reanalysis of the STAR*D data

Loading next page...
 
/lp/springer_journal/predicting-relapse-with-individual-residual-symptoms-in-major-Lx8U4y9OJ0
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2017 by Springer-Verlag Berlin Heidelberg
Subject
Biomedicine; Neurosciences; Pharmacology/Toxicology; Psychiatry
ISSN
0033-3158
eISSN
1432-2072
D.O.I.
10.1007/s00213-017-4634-5
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial